View in EDS HTML Full Text PDF Full Text

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.

Saved in:
Bibliographic Details
Title: Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Authors: Fierro CA; Johnson County Clin-Trials, Lenexa, Kansas, USA., Sarnecki M; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Vaccines, Bern, Switzerland., Doua J; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium., Spiessens B; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium., Go O; Janssen Research and Development, Raritan, New Jersey, USA., Davies TA; Janssen Research and Development, Raritan, New Jersey, USA., van den Dobbelsteen G; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Leiden, The Netherlands., Poolman J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Leiden, The Netherlands., Abbanat D; Janssen Research and Development, Raritan, New Jersey, USA., Haazen W; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium.
Source: Open forum infectious diseases [Open Forum Infect Dis] 2023 Aug 11; Vol. 10 (8), pp. ofad417. Date of Electronic Publication: 2023 Aug 11 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37608916
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fierro+CA%22">Fierro CA</searchLink>; Johnson County Clin-Trials, Lenexa, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Sarnecki+M%22">Sarnecki M</searchLink>; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Vaccines, Bern, Switzerland.<br /><searchLink fieldCode="AU" term="%22Doua+J%22">Doua J</searchLink>; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Spiessens+B%22">Spiessens B</searchLink>; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Go+O%22">Go O</searchLink>; Janssen Research and Development, Raritan, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Davies+TA%22">Davies TA</searchLink>; Janssen Research and Development, Raritan, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22van+den+Dobbelsteen+G%22">van den Dobbelsteen G</searchLink>; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Poolman+J%22">Poolman J</searchLink>; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Abbanat+D%22">Abbanat D</searchLink>; Janssen Research and Development, Raritan, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Haazen+W%22">Haazen W</searchLink>; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101637045%22">Open forum infectious diseases</searchLink> [Open Forum Infect Dis] 2023 Aug 11; Vol. 10 (8), pp. ofad417. <i>Date of Electronic Publication: </i>2023 Aug 11 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Published+by+Oxford+University+Press+on+behalf+of+the+Infectious+Diseases+Society+of+America%22">Published by Oxford University Press on behalf of the Infectious Diseases Society of America </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101637045 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2328-8957 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223288957%22">23288957 </searchLink><i>NLM ISO Abbreviation: </i>Open Forum Infect Dis <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37608916
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/ofid/ofad417
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: ofad417
    Titles:
      – TitleFull: Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fierro CA
      – PersonEntity:
          Name:
            NameFull: Sarnecki M
      – PersonEntity:
          Name:
            NameFull: Doua J
      – PersonEntity:
          Name:
            NameFull: Spiessens B
      – PersonEntity:
          Name:
            NameFull: Go O
      – PersonEntity:
          Name:
            NameFull: Davies TA
      – PersonEntity:
          Name:
            NameFull: van den Dobbelsteen G
      – PersonEntity:
          Name:
            NameFull: Poolman J
      – PersonEntity:
          Name:
            NameFull: Abbanat D
      – PersonEntity:
          Name:
            NameFull: Haazen W
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 08
              Text: 2023 Aug 11
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 2328-8957
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Open forum infectious diseases
              Type: main
ResultId 1